Navigation Links
LCA-Vision Urges Stockholders to Take No Action Regarding the Joffe Group's Threatened Consent Solicitation
Date:12/29/2008

CINCINNATI, Dec. 29 /PRNewswire-FirstCall/ -- The LCA-Vision Inc. (Nasdaq: LCAV) Board of Directors strongly opposes the consent solicitation threatened by the Joffe group. The Board believes that the Company has undertaken a prudent and achievable strategic plan to return the Company to profitability and that the Joffe intervention is a poorly designed effort to take control of your Company. The Board further believes that the Joffe effort is an undue distraction to the Company that would damage shareholder value. The Board of Directors strongly encourages stockholders to refrain from taking any action regarding the Joffe group's consent solicitation until they have had the benefit of the Board's recommendation and accompanying explanation.

About LCA-Vision Inc./LasikPlus(R)

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus(R) brand, operates 77 LasikPlus(R) fixed-site laser vision correction centers in 33 states and 59 markets in the United States and a joint venture in Canada. Additional company information is available at http://www.lca-vision.com/ and http://www.lasikplus.com/.

Disclaimer

In connection with a possible consent solicitation by certain stockholders to remove and replace the Board of Directors of the Company, the Company plans to file a consent revocation statement solicitation with the Securities and Exchange Commission. THE COMPANY URGES INVESTORS TO READ THE CONSENT REVOCATION STATEMENT (INCLUDING ANY SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders will be able to obtain, free of charge, copies of the consent revocation statement and any other documents filed by the Company with the SEC in connection with the consent solicitation at the SEC's website at http://www.sec.gov and at the Company's website at http://www.lasikplus.com.

LCA-Vision Inc. and its directors and certain executive officers may be deemed to be participants in the solicitation of consent revocations from stockholders. Information regarding the names of the Company's directors and executive officers and their respective interests in the Company by security holdings or otherwise is set forth in the Company's proxy statement relating to the 2008 annual meeting of stockholders, which may be obtained free of charge at the SEC's website at http://www.sec.gov and the Company's website at http://www.lasikplus.com or by contacting Georgeson, 199 Water Street, 26th Floor, New York, NY 10038 by calling (212) 440-9800 (bankers and brokers) or toll-free (800) 457-0109 (all others). Additional information regarding the interests of such potential participants will be included in the consent revocation statement and other relevant documents to be filed with the SEC in connection with the Consent Solicitation.

Earning Trust Every Moment.

Transforming Lives Every Day.

        For Additional Information

        Company Contact:           Investor Relations Contact:
        Barb Kise                  Jody Cain
        513-792-9292               310-691-7100


'/>"/>
SOURCE LCA-Vision Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against LCA-Vision Inc.
2. LCA-Vision Announces Upcoming Investment Community Events
3. LCA-Vision Reports Fourth Quarter and Full-Year 2007 Financial Results
4. LCA-Vision Announces Quarterly Dividend Payment
5. LCA-Vision Announces the Opening of its 74th LasikPlus Vision Center in Des Moines, Iowa
6. LCA-Vision Announces the Opening of its 75th LasikPlus(R) Vision Center in Tulsa, Oklahoma
7. LCA-Vision Announces the Opening of its 76th LasikPlus(R) Vision Center in Woodbridge, New Jersey
8. LCA-Vision to Present at the Bank of America 2008 Health Care Conference
9. LCA-Vision Conducts 2008 Annual Stockholder Meeting
10. LCA-Vision Announces Upcoming Investment Community Events
11. LCA-Vision Announces CFO Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... services to communities in east Texas, is launching a regional charity effort to ... Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 ...
(Date:8/18/2017)... Bedford, TX (PRWEB) , ... August 18, 2017 , ... ... serves communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized ... her husband. , In early June of this year, Christina and her children returned ...
(Date:8/18/2017)... ... 2017 , ... Alcovit, a lime-flavored beverage that rids the body of toxins ... product now available through Jet.com. , After 25 years of development, the company ... designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Dangerous Inheritance”: a ... author, Diane Winters. Diane is from Southwest Nebraska where she was raised on ... and family. The story is fictional, but the friendships and mantra of ‘neighbors ...
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, ... yet effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)...   Marshall County Hospital in Benton, Kentucky has added ... hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ultraviolet ... such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology: